Ono Pharmaceutical ADR Representing 1/3rd Ord Shs (OPHLY) Stock Price & News

Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka. Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948. Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen. Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb. In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia

About Ono Pharmaceutical ADR Representing 1/3rd Ord Shs

CEOGyo Sagara | Gyo Sagara

Employees4.21 мян

Founded1717

HeadquartersОсака, Osaka, Япон

SectorPharmaceutical industry

Websiteono-pharma.com

Revenue

Net income

All values in JPY	2025 оны 9-р сар	2025 оны 12-р сар	2026 оны 3-р сар	2026 оны 6-р сар
Revenue	129.60Т	139.90Т	118.75Т	116.16Т
Cost of goods sold	34.96 тэрбум	36.68 тэрбум	33.06 тэрбум	28.68 тэрбум
Cost of revenue	34.96 тэрбум	36.68 тэрбум	33.06 тэрбум	28.68 тэрбум
Research and development expenses	34.77 тэрбум	33.53 тэрбум	42.49 тэрбум	32.40 тэрбум
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	30.08 тэрбум	31.73 тэрбум	27.70 тэрбум	23.90 тэрбум
Operating expense	64.56 тэрбум	67.00 тэрбум	77.09 тэрбум	56.83 тэрбум
Total operating expenses	99.53 тэрбум	103.68Т	110.15Т	85.51 тэрбум
Operating income	30.07 тэрбум	36.22 тэрбум	8.60 тэрбум	30.65 тэрбум
Other non operating income	-	-	318.00 сая	-2.00 сая
EBT including unusual items	29.52 тэрбум	37.20 тэрбум	3.28 тэрбум	31.25 тэрбум
EBT excluding unusual items	29.52 тэрбум	37.20 тэрбум	8.77 тэрбум	31.25 тэрбум
Income tax expense	7.17 тэрбум	8.31 тэрбум	2.24 тэрбум	7.09 тэрбум
Effective tax rate	24.30%	22.35%	68.23%	22.68%
Other operating expenses	-291.00 сая	1.73 тэрбум	3.81 тэрбум	526.00 сая
Net income	22.42 тэрбум	28.86 тэрбум	818.00 сая	24.15 тэрбум
Net profit margin	17.30%	20.63%	0.69%	20.79%
Earnings per share	-	-	-	-
Interest and investment income	677.00 сая	1.39 тэрбум	195.00 сая	1.38 тэрбум
Interest expense	-1.23 тэрбум	-408.00 сая	-34.00 сая	-783.00 сая
Net interest expenses	-549.00 сая	979.00 сая	161.00 сая	598.00 сая
Depreciation and amortization charges	-	-	3.10 тэрбум	-
EBITDA	39.39 тэрбум	45.82 тэрбум	18.21 тэрбум	39.63 тэрбум
Gain or loss from assets sale	-	-	2.20 тэрбум	-

Ask anything